Neue öffentlich-private Partnerschaft zur Entwicklung von Medikamenten gegen parasitäre Wurminfektionen lanciert

Genf – 28. November 2019
Ein neues Konsortium bestehend aus Forschungsinstituten, Universitäten, gemeinnützigen Organisationen und Pharmaunternehmen hat sich zusammengeschlossen, um neue Medikamente gegen Infektionen verursacht durch parasitäre Würmer (Helminthen) zu entwickeln. Zu diesen Krankheiten zählen die Flussblindheit und lymphatische Filariose sowie Infektionen mit Haken- und Peitschenwürmern. Fast eine Milliarde Menschen weltweit sind betroffen.

Public-private partnership launched to develop new drugs for roundworm infections

Geneva – 28 November 2019
“Pan-nematode” drug development platform is part of Europe’s Horizon 2020 programme
A new consortium of research institutes, universities, not-for-profit organizations, and pharmaceutical companies has teamed up to develop novel drugs for infections caused by parasitic worms (helminths), a debilitating group of diseases that includes river blindness, lymphatic filariasis, as well as infection with hookworm and whipworm, which together affect close to a billion people.

DNDi receives $29 million to fast-track the development of drugs to help eliminate sleeping sickness and river blindness

Geneva/Seattle – 25  November 2019

DNDi has been awarded $29.2 million to accelerate the development of innovative new drugs for patients in sub-Saharan Africa with sleeping sickness (human African trypanosomiasis – $15 million) and river blindness (onchocerciasis – $14.2 million) by the Bill & Melinda Gates Foundation These two parasitic diseases could be eliminated if new patient care tools are brought to bear.

Study shows that African eye worm threatens elimination of river blindness

Washington DC, USA – 20 November 2019
Over four million people will be infected with river blindness in 2025 in areas where African eye worm is present, according to new modelling
Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or ‘African eye worm’, according to a study published in Clinical Infectious Diseases.

ASTMH 2019

68th Annual Meeting

20-24 November 2019
National Harbor, USA

  • Symposium on tools to accelerate elimination of onchocerciasis
  • Presentations on onchocerciasis, lymphatic filariasis, leishmaniasis, clinical trials, and Chagas disease.

ड्रग्स फ़ॉर नेग्लेक्टेड डिज़ीज़ेज़ इनिशिएटिव व द बीएमजे ने दक्षिण एशिया में उपेक्षित बीमारियों व नयी खोज पर ख़ास संकलन जारी किया

23 जनवरी 2019, नयी दिल्ली

दक्षिण एशिया में उपेक्षित बीमारियों के उन्मूलन के लिए नवीनता/ नए प्रयोग महत्वपूर्ण हैं |

ड्रग्स फ़ॉर नेग्लेक्टेड डिज़ीज़ेज़ इनिशिएटिव (डीएनडीआई) ने बीएमजे (ब्रिटिश मेडिकल जर्नल) के सहयोग से ‘नेग्लेक्टेड डिज़ीज़ेज़ एंड इनोवेशन इन साउथ एशिया’ नाम का एक ख़ास संकलन प्रकाशित किया है | संकलन में दक्षिण एशिया व दुनिया भर के लगभग 30 लेखकों ने इस क्षेत्र में उपेक्षित मरीजों का स्वास्थ्य सुधारने के लिए शोध की प्राथमिकताओं के साथ ही कार्रवाई के लिए सिफारिशों की पहचान भी की है |

Drugs for Neglected Diseases initiative and The BMJ launch a special collection on neglected diseases and innovation in South Asia

New Delhi- 23 January 2019
Research and policy Innovation is vital for sustained control & elimination of neglected diseases in South Asia
DNDi has launched a special collection of articles entitles ‘Neglected Diseases and Innovation in South Asia’ published today by The BMJ. The collection brings together over 30 authors from across South Asia and internationally, to identify research priorities and recommendations for action to improve the health of neglected patients in the region. The collection maps progress in the control or elimination of neglected diseases such as lymphatic filariasis, kala-azar, and snakebites in the region, and highlights the growing challenge of antimicrobial resistance.